ILMN vs PSNL
ILMN: Illumina is the global leader in DNA sequencing and array technologies that are foundational to modern genomics research and clinical diagnostics. PSNL: A genomic testing company enabling precision oncology through ultra-sensitive liquid biopsy and tumor sequencing to detect cancer recurrence and guide personalized treatment decisions.
Side-by-side fundamentals
| Metric | ILMN | PSNL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $190.87 | $12.47 | |
| Market cap as of 2026-07-23 | $29.2B | $1.3B | |
| P/E as of 2026-07-23 | 34.24 | n/a | |
| PEG as of 2026-07-23 | 2.91 | n/a | |
| Net margin as of 2026-07-23 | +19.4% | -148.1% | ILMN higher |
| Gross margin as of 2026-07-23 | +66.7% | +13.7% | ILMN higher |
| Operating margin as of 2026-07-23 | +19.3% | -158.9% | ILMN higher |
| ROE as of 2026-07-23 | +34.0% | -43.5% | ILMN higher |
| ROA as of 2026-07-23 | +13.4% | -32.9% | ILMN higher |
| Debt / equity as of 2026-07-23 | 0.74 | 0.00 | PSNL lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.3% | -24.7% | ILMN higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | +2.3% | PSNL higher |
| Beta as of 2026-07-23 | 1.47 | 2.29 | |
| 1-year return as of 2026-07-22 close | +87.1% | +93.9% | PSNL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.